Clinical Trials Logo
  1. Home
  2. Cytomegalovirus Infections
  3. NCT01535885

Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV — ACE  

Cytomegalovirus Infections Clinical Trial

Official title:
A Phase I Study Of Using Multi-virus Cytotoxic T-cells Following T-cell Depleted Allogeneic Hematopoietic Progenitor Cell Transplantation For Prophylaxis Against Specific Pathogens- Epstein Barr Virus, Adenovirus, And Cytomegalovirus (ACE)

Clinical Trial Summary

This protocol is a phase I study. Patients may be eligible for an infusion of Multi-virus Cytotoxic T Lymphocytes (CTL) if they received a T-cell depleted (TCD) transplant from a related family member or an unrelated donor. Recipients of these types of transplants are severely immune compromised during the early post-transplant period and are more susceptible to certain viruses. The investigators hypothesize that the adoptive transfer of Cytotoxic T Lymphocytes (CTL) against certain viruses: Adenovirus, Cytomegalovirus and Epstein Barr Virus (Ad, CMV, and EBV) will be safe with regard to producing graft versus host disease (GVHD) or other infusion related toxicities.

Clinical Trial Description

Within this clinical trial, the investigators will test the hypotheses that the administration of CTLs for prophylaxis against Ad, CMV and EBV in recipients of TCD-HPCT will be safe and well tolerated. Graded doses of Multi-Virus CTL will be administered to recipients of genotypically haploidentical or mismatched unrelated TCD grafts. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01535885
Study type Interventional
Source Medical College of Wisconsin
Contact
Status Completed
Phase Phase 1
Start date February 2012
Completion date October 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03950414 - A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients Phase 1
Recruiting NCT04690933 - AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
Withdrawn NCT04936971 - Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response Phase 4
Recruiting NCT02671318 - Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Phase 4
Completed NCT01325636 - Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus Phase 1/Phase 2
Recruiting NCT00228202 - Genotyping of Cytomegalovirus From Patients in Israel N/A
Completed NCT00031421 - Neonatal CMV-Ganciclovir Follow-up Study N/A
Completed NCT00005496 - Inflammation, Infection, and Future Cardiovascular Risk N/A
Terminated NCT03262194 - Relevance of Gastric Aspirate in HCMV Detection
Completed NCT04478474 - Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
Recruiting NCT05370976 - Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. Phase 2
Active, not recruiting NCT02943057 - Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Phase 4
Completed NCT02538172 - Cell-mediated Immunity for Prevention of CMV Disease N/A
Completed NCT02642822 - The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University N/A
Completed NCT02134184 - The Influence of Chronic CMV Infection on Influenza Vaccine Responses Phase 4
Completed NCT00673868 - Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants Phase 1
Active, not recruiting NCT05089630 - A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults Phase 1/Phase 2
Not yet recruiting NCT06058858 - Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Active, not recruiting NCT04904614 - Letermovir Use in Heart Transplant Recipients Phase 4
Completed NCT01986010 - Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001) Phase 1